OTEurope

Newer techniques in lamellar surgery

Feb 18, 2009

Article

Newer techniques in lamellar surgery

Newer techniques in lamellar surgery, from the February 2009 issue of EyeWorld.

Please click here to read the full article.

Related Videos

Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology

Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany

Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London

Kasperi Kankare at the iCare booth at ESCRS

Scott D Barnes, MD, CMO of STAAR Surgical

Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO

Related Content

Study: Children with vision impairment have reduced quality of life

September 20th 2023

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

September 12th 2023

Bausch + Lomb launches MIEBO (perfluorohexyloctane ophthalmic solution) in US

September 12th 2023

Study: Children with vision impairment have reduced quality of life

September 20th 2023

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

September 12th 2023

Bausch + Lomb launches MIEBO (perfluorohexyloctane ophthalmic solution) in US

September 12th 2023

Study: Children with vision impairment have reduced quality of life

September 20th 2023

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

September 12th 2023

Bausch + Lomb launches MIEBO (perfluorohexyloctane ophthalmic solution) in US

September 12th 2023

Related Content

A child wearing glasses sits in a classroom among her peers who do not have glasses. Image credit: ©Drazen – stock.adobe.com

Study: Children with vision impairment have reduced quality of life

September 20th 2023

Research from Orbis International analyses the overall wellbeing of children with common childhood vision problems

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

A digital illustration of an eye with charts and numbers imposed atop it. Image credit: ©ArticMinimal – stock.adobe.com

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

The AI retinal scanning model will be free to use for all institutions

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022

A series of test tubes in a laboratory. Image credit: ©Vladislava – stock.adobe.com

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

September 12th 2023

Novartis acquired Gyroscope Holdings Limited from Syncona in February 2022

A patient administers eye drops to his own eye. Image credit: ©Krakenimages.com – stock.adobe.com

Bausch + Lomb launches MIEBO (perfluorohexyloctane ophthalmic solution) in US

September 12th 2023

According to Bausch + Lomb, MIEBO (perfluorohexyloctane ophthalmic solution), commercialised as EvoTears in Europe, is the first prescription eye drop that targets tear evaporation.

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.